US2016075706A1PendingUtilityA1
Compounds as modulators of ror gamma
Est. expiryApr 14, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Johanna BakonyiSteven Richard BrunetteDelphine CollinRobert Owen HughesXiang LiShuang LiangRobert SibleyMichael Robert TurnerLifen WuQiang Zhang
C07D 475/10A61K 31/33A61P 37/08A61P 37/02A61P 37/00A61P 3/10A61P 9/10A61P 37/06A61P 29/00A61P 27/02A61P 17/00A61P 11/02A61P 11/06A61P 19/02A61P 19/08A61P 1/00A61P 25/00A61P 17/06A61P 17/04A61P 13/12A61P 1/04C07D 487/04C07D 475/00A61K 31/519C07D 401/14
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
Claims
exact text as granted — not AI-modified1 - 23 . (canceled)
24 . A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
25 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
26 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
27 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
28 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
29 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
30 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
31 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
32 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
33 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
34 . The compound according to claim 24 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
35 . A pharmaceutical composition comprising the compound according to claim 24 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
36 . A pharmaceutical composition comprising the compound according to claim 25 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
37 . A pharmaceutical composition comprising the compound according to claim 26 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
38 . A pharmaceutical composition comprising the compound according to claim 27 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
39 . A pharmaceutical composition comprising the compound according to claim 28 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
40 . A pharmaceutical composition comprising the compound according to claim 29 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
41 . A pharmaceutical composition comprising the compound according to claim 30 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
42 . A pharmaceutical composition comprising the compound according to claim 31 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
43 . A pharmaceutical composition comprising the compound according to claim 32 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
44 . A pharmaceutical composition comprising the compound according to claim 33 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
45 . A method for treating an autoimmune disease or allergic disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound according to claim 24 , or a pharmaceutically acceptable salt thereof.
46 . The method according to claim 45 , wherein the autoimmune disease or allergic disorder is selected from rheumatoid arthritis, psoriasis, systemic lupus erythromatosis, lupus nephritis, scleroderma, asthma, allergic rhinitis, allergic eczema, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, type I diabetes, inflammatory bowel disease, graft versus host disease, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, uveitis and non-radiographic spondyloarthropathy.
47 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
48 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
49 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
50 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
51 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
52 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
53 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
54 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
55 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
56 . The method according to claim 45 , wherein the compound is
or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2016075706A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.